Sign in Subscribe
Diseases

Celiac Disease Treatment Market Set for Robust Growth Through 2034

Strategic Insights

— 2 min read

The celiac disease treatment market is rapidly expanding, driven by increasing awareness, rising prevalence, and breakthrough therapies from key pharmaceutical players. According to a recent report by DelveInsight, the US held the largest share of the celiac disease drugs market in 2023, accounting for approximately 70% of the total market across 7MM. The market in Japan was valued at approximately USD 1.5 billion, demonstrating significant regional market potential.

Key Takeaways:

  • The celiac disease treatment market is expected to witness continued innovation driven by enhanced understanding of disease pathogenesis, which involves a complex interaction between genetic factors and environmental triggers.
  • The market growth is supported by DelveInsight's comprehensive qualitative analysis using SWOT analysis and conjoint analysis approaches, evaluating multiple approved and emerging therapies based on relevant attributes.
  • The celiac disease market is poised for remarkable expansion and therapeutic innovation in the coming decade, driven by breakthrough therapies from key pharmaceutical players.
  • The cornerstone of celiac disease management remains a strict, lifelong gluten-free diet, which is essential for alleviating symptoms, promoting intestinal healing, and preventing long-term complications.
  • For patients experiencing celiac crisis or refractory celiac disease type II (RCD II), short-term use of corticosteroids like prednisolone may provide relief until the gluten-free diet becomes effective.
  • The celiac disease therapies pipeline is robust and promising, with several novel treatments in late-stage development, including Latiglutenase from Entero Therapeutics, TAK-101, TAK-227, and Zamaglutenase from Takeda, and PRV-015 (Provention Bio/Sanofi) and KAN-101 (Kanyos Bio/Anokion), among others.
  • These emerging therapies represent a different mechanistic approach to addressing the complex pathophysiology of celiac disease, with the potential to provide better management and outcomes for patients.
  • The celiac disease treatment market is highly competitive, with major players including Entero Therapeutics, Amgen/Provention Bio, Takeda, and Sanofi, all advancing a variety of therapies through robust R&D and strategic collaborations.

Statistics:

  • The celiac disease treatment market is expected to experience significant growth, with the global market size projected to reach approximately USD 2.5 billion by 2024.
  • The US held the largest share of the celiac disease drugs market in 2023, accounting for approximately 70% of the total market across 7MM.
  • The market in Japan was valued at approximately USD 1.5 billion, demonstrating significant regional market potential.
  • Approximately 1 in 100 people worldwide suffer from celiac disease, yet only about 30% are properly diagnosed.
  • The disease predominantly impacts females and is most commonly diagnosed in individuals aged 19-39, emphasizing the need for timely detection and management.
  • In Germany, approximately 60% of diagnosed cases are female, highlighting the gender-specific prevalence patterns across different regions.

Sources:

  • M2 PRESSWIRE-June 19, 2025-: Celiac Disease Treatment Market Set for Robust Growth Through 2034, Driven by Recent Developments in Clinical Development Pipeline | DelveInsight
  • DelveInsight's "Celiac Disease Market Insight, Epidemiology And Market Forecast - 2034" report
  • M2 Communications
  • www.abnewswire.com
  • ((M2 Communications disclaims all liability for information provided within M2 PressWIRE. Data supplied by named party/parties. Further information on M2 PressWIRE can be obtained at http://www.m2.co.uk on the world wide web. Inquiries to info@m2.co.uk)).

Read more